Featured Research

from universities, journals, and other organizations

TB drug could reduce mortality for multidrug-resistant (MDR-TB) and extremely drug-resistant (XDR-TB) cases

Date:
September 27, 2012
Source:
European Lung Foundation
Summary:
Results from an observational study evaluating a new anti-TB drug have found that the treatment can improve outcomes and reduce mortality among patients with both MDR-TB and XDR-TB.

Results from an observational study evaluating a new anti-TB drug have found that the treatment can improve outcomes and reduce mortality among patients with both MDR-TB and XDR-TB.

The research, published online ahead of print today (27 September 2012) in the European Respiratory Journal, suggests a drug called delamanid could have a public health benefit for MDR-TB and also for XDR-TB, as few effective treatment options are currently available.

Over the past two decades, multidrug-resistant TB (MDR-TB) has emerged as a significant public health threat, with strains of TB growing increasingly resistant to first-line drugs. MDR-TB hampers progress towards the global elimination of TB and recently it has further evolved into an even more resistant form, called extensively drug-resistant tuberculosis (XDR-TB).

The WHO Global Plan to Stop TB 2011-2015 has called for urgent development of new drugs with novel mechanisms of action to treat all forms of TB, including MDR and XDR-TB.

A randomised control trial has previously evaluated the effectiveness of 2 months treatment with different doses of the drug. The new study followed the same patients and observed the outcomes of their treatment for a further 24 months.

421 patients took part in the observational study and researchers examined the effects of delamanid when taken in combination with a World Health Organization-recommended background treatment regimen. The researchers classified the patients into either a favourable outcomes group, where the patient was cured or completed the treatment, or an unfavourable outcome, where the patient had failed the treatment course, defaulted or died.

The results found that 74.5% of patients taking delamanid for more than 6 months had favourable outcomes. This compared to 55% of patients taking the drug for less than 2 months. Furthermore, only two patient deaths occurred in the long-term group, compared to 19 in the short-term treatment group.

In the subset of patients suffering with XDR-TB, 61.4% of patients in the long-term group experienced favourable outcomes, compared with 50% in the short-term group. Mortality was also reduced within this subset.

Lead author, Vija Skripconoka from the Riga East University Hospital, said: "The observational study has shown that when delamanid is taken for at least 6 months with a WHO-recommended background treatment regimen, it can improve outcomes for patients with MDR-TB and XDR-TB. This is extremely positive news given that similar studies of different treatments rarely report favourable outcomes above 70% or mortality rates below 15%. The 1% mortality rate measured in this study is very promising. A further randomised-control study is currently enrolling a large group of people to confirm delamanid's effectiveness and monitor side-effects."


Story Source:

The above story is based on materials provided by European Lung Foundation. Note: Materials may be edited for content and length.


Journal Reference:

  1. Vija Skripconoka, Manfred Danilovits, Lea Pehme, Tarmo Tomson, Girts Skenders, Tiina Kummik, Andra Cirule, Vaira Leimane, Anu Kurve, Klavdia Levina, Lawrence Geiter, Davide Manissero, Charles D. Wells. Delamanid Improves Outcomes and Reduces Mortality for Multidrug-Resistant Tuberculosis. European Respiratory Journal, 2012; DOI: 10.1183/09031936.00125812

Cite This Page:

European Lung Foundation. "TB drug could reduce mortality for multidrug-resistant (MDR-TB) and extremely drug-resistant (XDR-TB) cases." ScienceDaily. ScienceDaily, 27 September 2012. <www.sciencedaily.com/releases/2012/09/120926213755.htm>.
European Lung Foundation. (2012, September 27). TB drug could reduce mortality for multidrug-resistant (MDR-TB) and extremely drug-resistant (XDR-TB) cases. ScienceDaily. Retrieved September 23, 2014 from www.sciencedaily.com/releases/2012/09/120926213755.htm
European Lung Foundation. "TB drug could reduce mortality for multidrug-resistant (MDR-TB) and extremely drug-resistant (XDR-TB) cases." ScienceDaily. www.sciencedaily.com/releases/2012/09/120926213755.htm (accessed September 23, 2014).

Share This



More Health & Medicine News

Tuesday, September 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Costs Keep Mounting

Ebola Costs Keep Mounting

Reuters - Business Video Online (Sep. 23, 2014) The WHO has warned up to 20,000 people could be infected with Ebola over the next few weeks. As Sonia Legg reports, the implications for the West African countries suffering from the disease are huge. Video provided by Reuters
Powered by NewsLook.com
Liberia Pleads for Help to Fight Ebola

Liberia Pleads for Help to Fight Ebola

AP (Sep. 22, 2014) Liberia's finance minister is urging the international community to quickly follow through on pledges of cash to battle Ebola. Bodies are piling up in the capital Monrovia as the nation awaits more help. (Sept. 22) Video provided by AP
Powered by NewsLook.com
Ebola Doctor Says Border Controls Critical

Ebola Doctor Says Border Controls Critical

AP (Sep. 22, 2014) A Florida doctor who helped fight the expanding Ebola outbreak in West Africa says the disease can be stopped, but only if nations quickly step up their response and make border control a priority. (Sept. 22) Video provided by AP
Powered by NewsLook.com
Global Ebola Aid Increasing But Critics Say It's Late

Global Ebola Aid Increasing But Critics Say It's Late

Newsy (Sep. 21, 2014) More than 100 tons of medical supplies were sent to West Africa on Saturday, but aid workers say the global response is still sluggish. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins